Engineered immune cells take on deadly brain cancer in new trial
NCT ID NCT07180927
First seen Nov 01, 2025 · Last updated Jun 12, 2026 · Updated 27 times
Summary
This study tests a new treatment called 4sCAR-DLL3 CAR-T therapy for people with certain brain tumors, including glioblastoma and DIPG. The therapy uses a patient's own immune cells that are modified in a lab to target a protein called DLL3 found on tumor cells. The goal is to see if this approach is safe and can shrink tumors. About 30 patients aged 2 to 70 with recurrent or hard-to-treat brain tumors will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA OF CEREBELLUM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shenzhen Geno-immuno Medical Institute
RECRUITINGShenzhen, Guangdong, 518000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.